Biomea Fusion Inc
NASDAQ:BMEA

Watchlist Manager
Biomea Fusion Inc Logo
Biomea Fusion Inc
NASDAQ:BMEA
Watchlist
Price: 1.26 USD -3.08% Market Closed
Market Cap: $89.1m

Biomea Fusion Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biomea Fusion Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Biomea Fusion Inc
NASDAQ:BMEA
Research & Development
-$118.1m
CAGR 3-Years
-62%
CAGR 5-Years
-155%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

Biomea Fusion Inc
Glance View

Market Cap
89.1m USD
Industry
Biotechnology

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.

BMEA Intrinsic Value
HIDDEN
Show

See Also

What is Biomea Fusion Inc's Research & Development?
Research & Development
-118.1m USD

Based on the financial report for Dec 31, 2024, Biomea Fusion Inc's Research & Development amounts to -118.1m USD.

What is Biomea Fusion Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-155%

Over the last year, the Research & Development growth was -15%. The average annual Research & Development growth rates for Biomea Fusion Inc have been -62% over the past three years , -155% over the past five years .

Back to Top